Literature DB >> 27533878

Detection of Occult Invasion in Melanoma In Situ.

Michael J Bax1, Timothy M Johnson2, Paul W Harms3, Jennifer L Schwartz1, Lili Zhao4, Douglas R Fullen3, May P Chan3.   

Abstract

Importance: It is unclear why some patients with in situ melanoma develop metastases. Few reports demonstrate occult invasion with immunohistochemistry staining, which were discordant with reports interpreting such staining as false-positive. Objective: To investigate the occurrence of occult invasive disease within in situ melanoma by using methods to circumvent potential limitations in prior study designs. Design, Setting, and Participants: Unequivocal in situ melanoma without associated nevi or regression was identified using a consecutive sample of 33 cases plus 1 index case in an academic medical center. After cutting deeper into the most representative tissue block, 3 sequential slides were stained with hematoxylin-eosin (H-E), melanoma antigen (melan-A), and again with H-E. Melan-A-stained slides showing definitive invasion were double-stained with Sry-related HMg-Box gene 10 (SOX10) to confirm the melanocytic nature of the cells of interest. The study evaluated the possibilities of occult invasion detected by immunohistochemistry, sectioning deeper into the tissue block, or both. Slides were independently scored by 3 dermatopathologists with interrater reliability assessed. The study was conducted from January 1, 2012, to July 31, 2014. Main Outcomes and Measures: Assessment of the occurrence of occult invasion, diagnosis of invasion by immunohistochemistry alone vs cutting deeper into the tissue block, and occurrence of false-positive results using immunohistochemistry alone.
Results: Occult invasive melanoma was detected in 11 of 33 consecutive cases (33%) of previously diagnosed unequivocal in situ melanoma. Six of 11 melanomas (55%) were diagnosable only by immunohistochemistry. The remaining 5 tumors (45%) were diagnosable by both melan-A and H-E staining, likely as a result of simply cutting deeper into the tissue block. Four cases (12%) showed a few melan-A-positive cells in the dermis, which was insufficient for a diagnosis of invasive melanoma and most consistent on a cytomorphologic basis with occult nevi. Conclusions and Relevance: Although rare, in situ melanoma may metastasize. Occult microinvasion was demonstrated in up to one-third of the specimens in the present study, which provides a plausible explanation for this adverse event. Thus, history and physical examination including regional lymph nodes, education, and surveillance recommendations should be based on a very low, but not zero, risk of metastasis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27533878     DOI: 10.1001/jamadermatol.2016.2668

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  6 in total

1.  Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.

Authors:  Jessica M Donigan; Mark A Hyde; David E Goldgar; Michael L Hadley; Marianne Bowling; Glen M Bowen
Journal:  JAMA Dermatol       Date:  2018-08-01       Impact factor: 10.282

2.  Nine per cent of biopsy-proven lentigo maligna lesions are reclassified as lentigo maligna melanoma after surgery.

Authors:  J Zoutendijk; D Tio; S Koljenovic; R R van den Bos
Journal:  Br J Dermatol       Date:  2019-04-15       Impact factor: 9.302

3.  Genetic predisposition and prediction protocol for epithelial neoplasms in disease-free individuals: A systematic review.

Authors:  J Gowthami; N Gururaj; V Mahalakshmi; R Sathya; T R Sabarinath; Daffney Mano Doss
Journal:  J Oral Maxillofac Pathol       Date:  2020-09-09

4.  Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.

Authors:  Yukiko Kiniwa; Kenta Nakamura; Asuka Mikoshiba; Atsuko Ashida; Yasuyuki Akiyama; Atsushi Morimoto; Ryuhei Okuyama
Journal:  BMC Cancer       Date:  2021-03-17       Impact factor: 4.430

5.  Clinical size is a poor predictor of invasion in melanoma of the lentigo maligna type.

Authors:  Cristian Navarrete-Dechent; Saud Aleissa; Karen Connolly; Brian P Hibler; Stephen W Dusza; Anthony M Rossi; Erica Lee; Kishwer S Nehal
Journal:  J Am Acad Dermatol       Date:  2020-10-20       Impact factor: 11.527

Review 6.  The Anticancer Properties of Tanshinones and the Pharmacological Effects of Their Active Ingredients.

Authors:  Li Fu; Bing Han; Yang Zhou; Jie Ren; Wenzhi Cao; Gopal Patel; Guoyin Kai; Jun Zhang
Journal:  Front Pharmacol       Date:  2020-03-19       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.